Trevena Inc (TRVN) was Reiterated by Needham to “Buy” while Lowering the Price Target of the company shares to $ 11 from a previous price target of $14 . Needham advised their investors in a research report released on May 17, 2016.
Many Wall Street Analysts have commented on Trevena Inc. Company shares were Reiterated by FBR Capital on May 17, 2016 to “Outperform”, Firm has raised the Price Target to $ 16 from a previous price target of $13 .FBR Capital Initiated Trevena Inc on Mar 29, 2016 to “Outperform”, Price Target of the shares are set at $16.
Trevena Inc closed down -0.5 points or -7.33% at $6.32 with 36,98,655 shares getting traded on Monday. Post opening the session at $5.6, the shares hit an intraday low of $5.58 and an intraday high of $6.69 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Dec 11, 2015, David Soergel (Sr. VP,Clinical Dev. & CMO) sold 27,217 shares at $10.55 per share price.
Trevena Inc. (Trevena) is a clinical-stage biopharmaceutical company. The Company discovers develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform the Company has identified and advanced three differentiated product candidates: TRV130 a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734 a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain and TRV027 a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R) inhibiting G protein signaling and activating b-arrestin signaling. The Company has also identified a new product candidate TRV250 a small molecule G protein biased ligand of the delta-opioid receptor program focused on central nervous system (CNS).